<DOC>
	<DOCNO>NCT02478008</DOCNO>
	<brief_summary>The purpose study evaluate initial short long-term safety performance CardiAQ™ Transcatheter Mitral Valve Implantation System use Transapical Delivery System . The study enroll patient moderate severe mitral valve regurgitation consider high extreme risk mortality morbidity conventional open heart surgery .</brief_summary>
	<brief_title>A Clinical Study CardiAQ™ TMVI System ( Transapical DS )</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Key NYHA Classification ≥ III Left Ventricular Ejection Fraction ≥ 30 % Mitral regurgitation ≥ Grade 3+ Subject meet anatomical eligibility criterion investigational device</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Transcatheter Mitral Valve Replacement</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Insufficiency</keyword>
	<keyword>Transapical</keyword>
</DOC>